Pharmaceutical Market Europe • February 2023 • 34-36
APPOINTMENTS
AstraZeneca AB
Per Alfredsson
AstraZeneca AB has appointed Per Alfredsson as its chief operating officer. Alfredsson, who has been with the company for over 25 years, will be maintaining his role as senior vice president for biologics operations and continue to lead its global production network for biologics. Throughout his time with AstraZeneca, Alfredsson also served as co-lead for the company’s COVID-19 vaccine programme, during which he led the establishment and start-up of a supply network of more than 25 partners across more than 15 countries. Prior to assuming his role of senior vice president in 2019, he led Europe, Middle East and Africa supply through a period of change. Within the company, he has also served in executive-level positions leading global supply chain and strategy, Sweden operations and iPR Pharmaceuticals.
Chiesi Group
Giuseppe Accogli
Chiesi Group has appointed Giuseppe Accogli as chief executive officer. Accogli joins the company with 25 years of international experience in the medtech sector, 15 of which he spent at Baxter International, serving most recently as executive vice president and chief operating officer. Prior to his time at Baxter, Accogli was at Italian medtechs Medtronic and Tyco Healthcare.
CureVac
Alexander Zehnder
CureVac has appointed Alexander Zehnder as chief executive officer. Zehnder has held roles in the pharmaceutical industry for over 20 years and joins the company from his most recent role as global head of oncology at Sanofi. He has also held a variety of roles at Roche/Genentech, including vice president, global product strategy and global franchise head of oncology drug Avastin.
LEX Diagnostics
Ed Farrell
LEX Diagnostics has appointed Ed Farrell as chief executive officer. Farrell brings over 25 years of life sciences experience to the company, having most recently held the role of chief operating officer at Klay Biotech. Prior to this, Farrell served as chief operating officer at Quotient for nine years, where he led the development and realisation of the company’s MosaiQ platform.
Allogene
Zachary Roberts
Allogene has appointed Zachary Roberts as executive vice president of research and development. Roberts joins the company from his most recent role of chief medical officer at Instil Bio, where he led development of both clinical and preclinical programmes. Prior to this, he held various roles at Kite Pharma, working on the company’s ZUMA trials across multiple indications for Yescarta.
Reset Pharmaceuticals
Innes Meldrum
Reset Pharmaceuticals has appointed Innes Meldrum as president and chief executive officer. Meldrum's most recent role was as senior vice president and chief commercial officer for Otsuka Pharmaceuticals, North America. Prior to this, he served as commercial vice president at Orexo after spending 11 years in roles at Novartis in the US and Switzerland.
Vaccitech
Nadège Pelletier
Vaccitech has appointed Nadège Pelletier as chief scientific officer. She will lead Vaccitech’s scientific teams in all phases of drug discovery and platform development, as well as build and oversee the strategic technical direction of the company. Pelletier joins Vaccitech from the Novartis Institutes for Biomedical Research and, prior to that, Roche Pharma Research and Early Development.
ADC Therapeutics
Mohamed Zaki
ADC Therapeutics has appointed Mohamed Zaki as chief medical officer. Zaki joins the company from his most recent role of vice president and global head of oncology development at AbbVie. Prior to this, he spent nine years at Celgene in increasingly senior roles in oncology and haematology development, and has also worked in clinical development at Sanofi-Aventis and Centocor.
MinervaX ApS
Lidia Oostvogels
MinervaX ApS has appointed Lidia Oostvogels as chief medical officer. Oostvogels brings over 25 years’ experience in vaccine development to her new role, having most recently served as senior vice president, area head, infectious diseases at CureVac AG. Prior to her time at CureVac, Oostvogels worked at GSK plc for more than 12 years, after spending nine years at Boehringer Ingelheim.
NICE
Jonathan Benger
The National Institute for Health and Care Excellence (NICE) has appointed Professor Jonathan Benger as its new chief medical officer. Benger is the former chief medical officer of NHS Digital and, prior to joining NICE, served as interim chief clinical information officer for NHS England.
He also held the position of national clinical director for urgent and emergency care at NHS England for almost six years. In his clinical work, Benger is a consultant in emergency medicine at the Bristol Royal Infirmary and does regular shifts with the Great Western Air Ambulance, which he founded as its first clinical director in 2007.
He is also professor of emergency care in the School of Health and Social Wellbeing at the University of the West of England, as well as a National Institute for Health Research senior investigator.
NICE
Helen Brown
NICE has appointed Helen Brown as chief people officer. Brown brings over 25 years’ experience in human resources to her new role, the last 12 of which have been spent at Medtronic as HR director, looking after three business units across Europe in neuroscience. Prior to this, Brown partnered with the business as HR director for the UK and Ireland.
Biogen
Priya Singhal
Biogen has appointed Priya Singhal as executive vice president, head of development. Singhal has held a variety of roles within the company, having most recently served as senior vice president and head of global safety and regulatory sciences. She has also held the role of head of research and development at Zafgen, as well as vice president of medical affairs at Vertex Pharmaceuticals.
STORM Therapeutics
Matthew Fyfe
STORM Therapeutics has appointed Matthew Fyfe as senior vice president of therapeutics. Fyfe has over 20 years’ experience in drug discovery and development. He most recently served as vice president, head of medicinal sciences at Sitryx therapeutics, prior to which he was head of chemistry and intellectual property at TopiVert, and he also held roles at Oryzon and Prosidion.
STORM Therapeutics
Beth Thomas
STORM Therapeutics has also appointed Beth Thomas as vice president of medicinal chemistry. Thomas, who has been with the company since 2016, has over 20 years of experience in medicinal and computational chemistry and will be responsible for medicinal chemistry strategy to enable the discovery and progression of clinical candidates from the company’s project portfolio.
bluebird bio
Joseph Vittiglio
bluebird bio has appointed Joseph Vittiglio as chief business and legal officer. Vittiglio brings more than 20 years of experience in the biopharma industry to the company, which he joins from his most recent role of chief business and legal officer at Finch Therapeutics. Prior to joining Finch, he was the general counsel and chief business officer for AMAG Pharmaceuticals.
Emmes
Matt Honan
Emmes has appointed Matt Honan as vice president and head of corporate development. Honan most recently served as senior director, mergers and acquisitions (M&A) at Quest Diagnostics, where he led cross-functional teams through the entire M&A life cycle. Prior to assuming that role, he held various M&A and finance positions of increasing responsibility at Quest.
Copley Scientific
Jamie Clayton
Copley Scientific has appointed Jamie Clayton as managing director. In his new role, Clayton will manage all day-to-day operations at Copley, from finance through to product development. Clayton's most recent role was as operations director at Freemans Technology, where he contributed to bringing the FT4 Powder Rheometer – a universal powder flow tester – to global prominence.
Provention Bio
Rita Jain
Provention Bio has appointed Rita Jain as a member of its board of directors. Jain, a board-certified rheumatologist, currently serves as a member of the supervisory board of AM Pharma and previously served on the board of directors of ChemoCentryx, until its acquisition by Amgen. Jain has also held roles at AbbVie, Abbott Laboratories, and G.D. Searle and Co.
Research Partnership
Gareth Phillips
Research Partnership has appointed Gareth Phillips as its new chief executive officer, with the co-founding directors of the business, Mary Assimakopoulos and Mark Jeffery, taking a step back from day-to-day operation. Phillips joins the company with extensive global experience, having spent 25 years in healthcare market research working with IMS Health – now IQVIA – and Synovate Healthcare, before it was acquired by Ipsos. He most recently served as UK managing director and head of EMEA at Ipsos, where he led the company to achieve consistent high growth over the past decade and helped expand its London team to more than 250 people. Prior to this, Phillips held roles at Synovate in the US, UK and Asia, and was the company’s managing director of Asia Pacific at the time of its integration into Ipsos.
SCIRIS
Isaac Batley
SCIRIS has appointed Isaac Batley as chief executive officer. Batley joins the agency with extensive experience in the healthcare industry and a 20-year career as a healthcare communications leader, which saw him successfully build his own agency that was acquired by Cello in 2014. Batley went on to lead Cello Health Communications Europe as CEO before serving as chairman of the company.
Fishawack Health
Elly Price
Fishawack Health has appointed Elly Price as managing director of global marketing. Price joins the agency with over 25 years’ experience running teams and agencies in Europe, the US and Australia across brand, medcomms, digital and PR. Price most recently held the role of managing director at CATO Creative. Prior to this, she served as business development director EU at ghg.
Ketchum
Katy Davidson
Ketchum has appointed Katy Davidson as health managing director. Davidson brings over 20 years’ experience in healthcare communications to her role, where she will be overseeing both the PR and medical comms teams. She most recently served as deputy managing director at Havas Life Medicom. Prior to this, she worked at agencies including Weber Shandwick and Shire Health – now Ogilvy Health.
IGNIFI
John Horn
IGNIFI has appointed John Horn as managing director. Horn has risen steadily through the ranks of the agency, having held a variety of roles for over 25 years. In his most recent position, Horn served as operations director, prior to which he held the role of client services manager. Horn’s appointment signals the stepping down of long-standing manager Dave Watson.
KVA
Jeremy Perrott
KVA has appointed Jeremy Perrott as a board advisor. Perrott joins the agency with over 40 years experience under his belt, and for the last 15 years he has served as global chief creative officer at McCann Health. Perrott is also a global ambassador for D&AD White Pencil and a regular award jury member and key mentor in the Smash Program.
90TEN
Siobhán Hoy
90TEN has appointed Siobhán Hoy as scientific director. Hoy joins the agency having worked in medical communications for seven years across a variety of therapy areas including gastroenterology, rheumatology and respiratory. Prior to joining 90TEN, she held the role of associate medical director at CMC Connect, where she had served in a number of roles since 2016.
90TEN
Katy Thom
90TEN has appointed Katy Thom as senior account manager in its PR division. Thom brings with her over ten years’ experience in healthcare communications in Australia and the UK, and joins the agency from BCW Global, where she also held the position of senior account manager. Prior to this, Thom served in a number of roles at SenateSHJ over five years.
IGNIFI
Jake Watson
IGNIFI has appointed Jake Watson as account executive. In his new role, Watson will be working alongside the agency’s group account director and account managers to provide day-to-day support for its healthcare clients. Watson joins the agency having recently completed a masters degree in international marketing after graduating from Newcastle University with a Bachelor of Arts.